NO334437B1 - Mikroporering av menneskehud for medikamentavlevering og overvåkningsanvendelser - Google Patents
Mikroporering av menneskehud for medikamentavlevering og overvåkningsanvendelser Download PDFInfo
- Publication number
- NO334437B1 NO334437B1 NO19980878A NO980878A NO334437B1 NO 334437 B1 NO334437 B1 NO 334437B1 NO 19980878 A NO19980878 A NO 19980878A NO 980878 A NO980878 A NO 980878A NO 334437 B1 NO334437 B1 NO 334437B1
- Authority
- NO
- Norway
- Prior art keywords
- skin
- stratum corneum
- energy
- micropore
- tissue
- Prior art date
Links
- 238000012544 monitoring process Methods 0.000 title description 19
- 238000012377 drug delivery Methods 0.000 title description 8
- 210000003491 skin Anatomy 0.000 claims abstract description 220
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 196
- 238000010438 heat treatment Methods 0.000 claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 238000002844 melting Methods 0.000 claims abstract description 17
- 230000008018 melting Effects 0.000 claims abstract description 16
- 210000001519 tissue Anatomy 0.000 claims description 105
- 210000003722 extracellular fluid Anatomy 0.000 claims description 73
- 238000001816 cooling Methods 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 239000011148 porous material Substances 0.000 claims description 14
- 230000035807 sensation Effects 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 5
- 230000004907 flux Effects 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 114
- 239000000126 substance Substances 0.000 abstract description 56
- 239000003814 drug Substances 0.000 abstract description 49
- 239000012491 analyte Substances 0.000 abstract description 43
- 239000003623 enhancer Substances 0.000 abstract description 37
- 239000012530 fluid Substances 0.000 abstract description 21
- 230000035699 permeability Effects 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000003628 erosive effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 description 94
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 93
- 210000004027 cell Anatomy 0.000 description 67
- 239000000975 dye Substances 0.000 description 67
- 210000002615 epidermis Anatomy 0.000 description 60
- 239000000523 sample Substances 0.000 description 59
- 210000004369 blood Anatomy 0.000 description 55
- 239000008280 blood Substances 0.000 description 55
- 239000010410 layer Substances 0.000 description 52
- 229940079593 drug Drugs 0.000 description 48
- 150000001875 compounds Chemical class 0.000 description 47
- RBTKNAXYKSUFRK-UHFFFAOYSA-N heliogen blue Chemical compound [Cu].[N-]1C2=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=NC([N-]1)=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=N2 RBTKNAXYKSUFRK-UHFFFAOYSA-N 0.000 description 39
- 238000002679 ablation Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- 238000012360 testing method Methods 0.000 description 28
- 238000002604 ultrasonography Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 230000006378 damage Effects 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 238000004088 simulation Methods 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 230000008569 process Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000003287 optical effect Effects 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 17
- 239000012528 membrane Substances 0.000 description 16
- 238000009826 distribution Methods 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- 210000004207 dermis Anatomy 0.000 description 14
- 238000009792 diffusion process Methods 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000000835 fiber Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000004888 barrier function Effects 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 231100000862 numbness Toxicity 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 230000037317 transdermal delivery Effects 0.000 description 10
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 229960000907 methylthioninium chloride Drugs 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000356 contaminant Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229960004194 lidocaine Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 231100000245 skin permeability Toxicity 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- -1 alcohol ester Chemical class 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000003961 penetration enhancing agent Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910002056 binary alloy Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000001678 irradiating effect Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000008058 pain sensation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 238000009834 vaporization Methods 0.000 description 4
- 230000008016 vaporization Effects 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241001310793 Podium Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000000736 corneocyte Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000003811 finger Anatomy 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 3
- 229960004657 indocyanine green Drugs 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005476 soldering Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 210000003813 thumb Anatomy 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- CEJANLKHJMMNQB-UHFFFAOYSA-M cryptocyanin Chemical compound [I-].C12=CC=CC=C2N(CC)C=CC1=CC=CC1=CC=[N+](CC)C2=CC=CC=C12 CEJANLKHJMMNQB-UHFFFAOYSA-M 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 210000000624 ear auricle Anatomy 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000000608 laser ablation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 241000427324 Glinus Species 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229940123452 Rapid-acting insulin Drugs 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- HJXPPCPJEYUQFQ-HNNXBMFYSA-N dodecyl (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound CCCCCCCCCCCCOC(=O)[C@@H]1CCC(=O)N1 HJXPPCPJEYUQFQ-HNNXBMFYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 150000004291 polyenes Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000003304 psychophysiological effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000002207 thermal evaporation Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/203—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00137—Details of operation mode
- A61B2017/00154—Details of operation mode pulsed
- A61B2017/00172—Pulse trains, bursts, intermittent continuous operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00761—Removing layer of skin tissue, e.g. wrinkles, scars or cancerous tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00765—Decreasing the barrier function of skin tissue by radiated energy, e.g. using ultrasound, using laser for skin perforation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Surgical Instruments (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Laser Surgery Devices (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52054795A | 1995-08-29 | 1995-08-29 | |
| US804395P | 1995-10-30 | 1995-10-30 | |
| PCT/US1996/013865 WO1997007734A1 (en) | 1995-08-29 | 1996-08-29 | Microporation of human skin for drug delivery and monitoring applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO980878D0 NO980878D0 (no) | 1998-02-27 |
| NO980878L NO980878L (no) | 1998-04-27 |
| NO334437B1 true NO334437B1 (no) | 2014-03-03 |
Family
ID=26677684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19980878A NO334437B1 (no) | 1995-08-29 | 1998-02-27 | Mikroporering av menneskehud for medikamentavlevering og overvåkningsanvendelser |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0858285A4 (pt) |
| JP (2) | JP3899427B2 (pt) |
| CN (1) | CN1174713C (pt) |
| AU (1) | AU707065B2 (pt) |
| BR (1) | BR9610012A (pt) |
| CA (1) | CA2199002C (pt) |
| ES (1) | ES2536459T3 (pt) |
| GB (1) | GB2307414B (pt) |
| HK (1) | HK1009321A1 (pt) |
| IL (1) | IL123379A (pt) |
| NO (1) | NO334437B1 (pt) |
| PT (1) | PT1563788E (pt) |
| TR (1) | TR199800347T1 (pt) |
| WO (1) | WO1997007734A1 (pt) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6315772B1 (en) | 1993-09-24 | 2001-11-13 | Transmedica International, Inc. | Laser assisted pharmaceutical delivery and fluid removal |
| CA2253549C (en) | 1996-06-18 | 2005-10-25 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
| CA2259437C (en) * | 1996-07-03 | 2006-12-05 | Altea Technologies, Inc. | Multiple mechanical microporation of skin or mucosa |
| ATE231015T1 (de) * | 1996-09-17 | 2003-02-15 | Deka Products Lp | System zur medikamentenabgabe durch transport |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| US6527716B1 (en) | 1997-12-30 | 2003-03-04 | Altea Technologies, Inc. | Microporation of tissue for delivery of bioactive agents |
| DK1314400T3 (da) * | 1996-12-31 | 2007-10-15 | Altea Therapeutics Corp | Mikroporering af væv til levering af bioaktive midler |
| US6027496A (en) * | 1997-03-25 | 2000-02-22 | Abbott Laboratories | Removal of stratum corneum by means of light |
| WO1999020181A1 (en) | 1997-10-21 | 1999-04-29 | Abbott Laboratories | Apparatus and method for the collection of interstitial fluids |
| US6155992A (en) * | 1997-12-02 | 2000-12-05 | Abbott Laboratories | Method and apparatus for obtaining interstitial fluid for diagnostic tests |
| US6918901B1 (en) | 1997-12-10 | 2005-07-19 | Felix Theeuwes | Device and method for enhancing transdermal agent flux |
| AU739616B2 (en) * | 1997-12-11 | 2001-10-18 | Alza Corporation | Device for enhancing transdermal agent flux |
| DK1037687T3 (da) | 1997-12-11 | 2009-01-26 | Alza Corp | Anordning til at forbedre et middels transdermale strömning |
| DE69831268T2 (de) * | 1997-12-11 | 2006-03-09 | Alza Corp., Palo Alto | Vorrichtung zur erhöhung des transdermalen wirkstoffeflusses |
| CA2323160A1 (en) * | 1998-03-06 | 1999-09-10 | Jonathan A. Eppstein | Photothermal structure for biomedical applications, and method therefor |
| US6173202B1 (en) * | 1998-03-06 | 2001-01-09 | Spectrx, Inc. | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
| US6530915B1 (en) | 1998-03-06 | 2003-03-11 | Spectrx, Inc. | Photothermal structure for biomedical applications, and method therefor |
| US6091975A (en) * | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| US6569157B1 (en) * | 1998-05-18 | 2003-05-27 | Abbott Laboratories | Removal of stratum corneum by means of light |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US7344499B1 (en) | 1998-06-10 | 2008-03-18 | Georgia Tech Research Corporation | Microneedle device for extraction and sensing of bodily fluids |
| US6077660A (en) * | 1998-06-10 | 2000-06-20 | Abbott Laboratories | Diagnostic assay requiring a small sample of biological fluid |
| CA2355044C (en) | 1998-07-14 | 2009-02-24 | Spectrx, Inc. | Controlled removal of biological membrane by pyrotechnic charge for transmembrane transport |
| US7384396B2 (en) | 1998-07-21 | 2008-06-10 | Spectrx Inc. | System and method for continuous analyte monitoring |
| EP1098594B1 (en) * | 1998-07-21 | 2007-12-12 | SPECTRX, Inc. | System and method for continuous analyte monitoring |
| WO2000013573A1 (en) * | 1998-09-04 | 2000-03-16 | Powderject Research Limited | Monitoring methods using particle delivery methods |
| US6468229B1 (en) | 1998-10-20 | 2002-10-22 | Abbott Laboratories | Apparatus and method for the collection of interstitial fluids |
| US6708060B1 (en) | 1998-11-09 | 2004-03-16 | Transpharma Ltd. | Handheld apparatus and method for transdermal drug delivery and analyte extraction |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| US6597946B2 (en) | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
| US6611706B2 (en) | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
| US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| JP4412874B2 (ja) | 1999-06-08 | 2010-02-10 | アルテア セラピューティクス コーポレイション | 薄膜組織インターフェイスデバイスを使用する生物学的膜のミクロポレーションのための装置、およびそのための方法 |
| US20030078499A1 (en) | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
| US6355054B1 (en) * | 1999-11-05 | 2002-03-12 | Ceramoptec Industries, Inc. | Laser system for improved transbarrier therapeutic radiation delivery |
| DE19963034A1 (de) | 1999-12-24 | 2001-06-28 | Roche Diagnostics Gmbh | System zur verbesserten Bestimmung des Glukosespiegels anhand von Messungen in interstitieller Flüssigkeit |
| IL136008A0 (en) | 2000-05-07 | 2001-05-20 | Elecsys Ltd | Electrically-mediated transdermal drug injection |
| US7597692B2 (en) | 2000-06-08 | 2009-10-06 | Massachusetts Institute Of Technology | Microscission processes and procedures |
| US6706032B2 (en) | 2000-06-08 | 2004-03-16 | Massachusetts Institute Of Technology | Localized molecular and ionic transport to and from tissues |
| AUPR044000A0 (en) * | 2000-09-28 | 2000-10-26 | Norwood Abbey Ltd | Diagnostic device |
| US6537243B1 (en) | 2000-10-12 | 2003-03-25 | Abbott Laboratories | Device and method for obtaining interstitial fluid from a patient for diagnostic tests |
| US6882884B1 (en) | 2000-10-13 | 2005-04-19 | Soundskin, L.L.C. | Process for the stimulation of production of extracellular dermal proteins in human tissue |
| US6733493B2 (en) * | 2000-11-16 | 2004-05-11 | Innotech Usa, Inc. | Laser skin perforator |
| US9302903B2 (en) | 2000-12-14 | 2016-04-05 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
| AU2002231207A1 (en) | 2000-12-21 | 2002-07-01 | Biovalve Technologies, Inc. | Microneedle array systems |
| JP4704583B2 (ja) * | 2001-02-28 | 2011-06-15 | 有限会社開発顧問室 | パッチテスト用シート |
| WO2003039620A2 (en) | 2001-05-17 | 2003-05-15 | Transpharma Medical Ltd. | Integrated transdermal drug delivery system |
| US6855117B2 (en) | 2001-08-01 | 2005-02-15 | Johnson & Johnson Consumer Companies, Inc. | Method of treating the skin of a subject |
| US6840910B2 (en) | 2001-08-01 | 2005-01-11 | Johnson & Johnson Consumer Companies, Inc. | Method of distributing skin care products |
| US6790179B2 (en) | 2001-08-01 | 2004-09-14 | Johnson & Johnson Consumer Companies, Inc. | Method of examining and diagnosing skin health |
| WO2003024507A2 (en) | 2001-09-19 | 2003-03-27 | Biovalve Technologies, Inc. | Microneedles, microneedle arrays, and systems and methods relating to same |
| AU2002330083A1 (en) | 2001-09-21 | 2003-04-01 | Biovalve Technologies, Inc. | Gas pressure actuated microneedle arrays, and systems and methods relating to same |
| CA2929300C (en) | 2002-03-11 | 2019-04-16 | Nitto Denko Corporation | Transdermal drug delivery patch system, method of making same and method of using same |
| US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
| EP1499255B1 (en) | 2002-04-19 | 2015-07-22 | Syneron Medical Ltd. | Handheld transdermal drug delivery and analyte extraction |
| US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| US8133505B2 (en) | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| IL152573A (en) | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
| IL152575A (en) | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | A system for passing through the skin of dry items or dried medicines |
| US7662404B2 (en) | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
| US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
| US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
| JP2007508914A (ja) * | 2003-10-24 | 2007-04-12 | アルザ・コーポレーシヨン | 経皮薬剤送達を促進するための装置及び方法 |
| BRPI0415466A (pt) * | 2003-10-24 | 2006-12-19 | Alza Corp | método e sistema de pré-tratamento para intensificar a distribuição transdérmica de fármacos |
| KR20070073918A (ko) | 2004-10-21 | 2007-07-10 | 바이엘 헬스케어 엘엘씨 | 체액 중 분석물 농도의 측정 방법 및 그의 시스템 |
| JP2006326147A (ja) * | 2005-05-30 | 2006-12-07 | Shingo Wakamatsu | レーザー治療装置 |
| TWI419717B (zh) * | 2005-06-17 | 2013-12-21 | Altea Therapeutics Corp | 滲透傳送系統及其使用方法 |
| JP5011936B2 (ja) * | 2006-10-11 | 2012-08-29 | パナソニック株式会社 | 血液検査装置 |
| JP5011935B2 (ja) * | 2006-10-11 | 2012-08-29 | パナソニック株式会社 | 血液検査装置 |
| CN101534895B (zh) * | 2006-11-14 | 2012-10-03 | 国立大学法人鹿儿岛大学 | 药物注入装置 |
| PT2152358E (pt) | 2007-04-27 | 2011-06-07 | Echo Therapeutics Inc | Dispositivo de permeação da pele para detecção de analito ou distribuição transdérmica de droga |
| WO2009047774A2 (en) | 2007-10-09 | 2009-04-16 | Transpharma Ltd. | Magnetic patch coupling |
| EP2205967B1 (en) | 2007-10-17 | 2013-05-01 | Syneron Medical Ltd. | Dissolution rate verification |
| WO2009060701A1 (ja) * | 2007-11-06 | 2009-05-14 | Konica Minolta Opto, Inc. | 微小開口形成装置およびそれを用いる体液収集システム |
| KR101464058B1 (ko) | 2007-12-05 | 2014-11-20 | 시네론 메디컬 리미티드 | 일회용 전자기 에너지 애플리케이터 및 그 사용방법 |
| GB0811856D0 (en) | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
| US8606366B2 (en) | 2009-02-18 | 2013-12-10 | Syneron Medical Ltd. | Skin treatment apparatus for personal use and method for using same |
| US20100256466A1 (en) * | 2009-04-02 | 2010-10-07 | Avraham Shekalim | Metabolite Management System |
| WO2011013118A2 (en) | 2009-07-27 | 2011-02-03 | Slatkine Michael | Methods and devices for tissue ablation |
| PT105635B (pt) * | 2011-04-19 | 2014-04-11 | Univ De Coimbra | Dispositivo para a administração eficiente de compostos na pele ou barreiras biológicas, ou através dessas, usando filmes finos absorventes de luz |
| PL3082634T3 (pl) | 2013-12-18 | 2021-10-18 | Novoxel Ltd. | Urządzenie do odparowywania tkanek |
| KR102170876B1 (ko) | 2014-09-15 | 2020-10-29 | 노보셀 리미티드 | 열 조직 기화 및 압축을 위한 방법 및 디바이스 |
| JP2017536142A (ja) * | 2014-09-15 | 2017-12-07 | ノヴォクセル リミテッド | 組織の熱外科的蒸散および切開のための方法および装置 |
| KR20170134480A (ko) * | 2015-03-03 | 2017-12-06 | 가이디드 테라피 시스템스, 엘.엘.씨. | 초음파의 보조로 약물을 조직으로 전달하기 위한 방법 및 시스템 |
| US10874325B2 (en) * | 2015-12-15 | 2020-12-29 | Koninklijke Philips N.V. | Surface treatment device and method |
| WO2017123954A1 (en) * | 2016-01-15 | 2017-07-20 | University Of Cincinnati | Advanced electroporation devices and methods for analyte access in biofluids |
| AU2017280014B2 (en) * | 2016-06-20 | 2022-05-26 | University Of North Texas | Laser-assisted machining (LAM) of non-monolithic composite bone material |
| FI127811B (en) * | 2016-11-21 | 2019-03-15 | Helsingin Yliopisto | APPARATUS FOR SAMPLING ONE OR MORE ANALYTICAL SAMPLES |
| EP3361402A1 (en) * | 2017-02-14 | 2018-08-15 | Roche Diabetes Care GmbH | A computer-implemented method and a portable device for analyzing glucose monitoring data indicative of a glucose level in a bodily fluid, and a computer program product |
| US11441994B2 (en) * | 2017-07-27 | 2022-09-13 | Tata Consultancy Services Limited | Method and system for in-silico design of skin electroporation |
| WO2019025610A1 (en) * | 2017-08-03 | 2019-02-07 | Fibrotx Oü | LATERAL FLOW DOSING AND DEVICE FOR SKIN CARE APPLICATION |
| CN109157280A (zh) * | 2018-08-10 | 2019-01-08 | 重庆大学 | 不可逆电穿孔组织消融效果动态实时评估设备 |
| WO2020264034A1 (en) * | 2019-06-28 | 2020-12-30 | Passport Technologies, Inc. | Methods and systems for controlling energy delivery to filament devices |
| TWI737122B (zh) * | 2019-08-02 | 2021-08-21 | 華廣生技股份有限公司 | 生物感測器之植入裝置 |
| CN110613893A (zh) * | 2019-10-31 | 2019-12-27 | 南京工业职业技术学院 | 一种新型励磁线圈 |
| CN111693434B (zh) * | 2020-06-19 | 2024-01-19 | 中建路桥集团有限公司 | 一种测试混凝土抗渗性能的实验装置 |
| CN114504373A (zh) * | 2020-11-16 | 2022-05-17 | 澳美力科技(成都)有限公司 | 一种新型射频变频美容仪 |
| CN112957124B (zh) * | 2021-01-30 | 2023-08-22 | 南京理工大学 | 一种能量靶向调控的离体激光生物组织焊接缝合方法 |
| CN115670642A (zh) * | 2021-05-20 | 2023-02-03 | 黄虹凤 | 保证高精度和高速度的激光切线装置 |
| CN114343839A (zh) * | 2021-12-30 | 2022-04-15 | 德州环球之光医疗科技有限公司 | 一种基于可调的螺旋线型激光光斑的治疗图形转换方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775361A (en) * | 1986-04-10 | 1988-10-04 | The General Hospital Corporation | Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport |
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| JP2798459B2 (ja) * | 1988-01-21 | 1998-09-17 | マサチユセツツ・インスチチユート・オブ・テクノロジー | エレクトロポレーションを利用した診断装置及び分子の組織内移動装置 |
| US5139023A (en) | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
| US5016615A (en) * | 1990-02-20 | 1991-05-21 | Riverside Research Institute | Local application of medication with ultrasound |
| US5115805A (en) * | 1990-02-23 | 1992-05-26 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
| GB9014307D0 (en) | 1990-06-27 | 1990-08-15 | Scient Generics Ltd | Method of treatment and compositions therefor |
| JP3189337B2 (ja) * | 1991-11-08 | 2001-07-16 | 日本電気株式会社 | 皮膚角層の除去器具および除去方法 |
| US5344418A (en) * | 1991-12-12 | 1994-09-06 | Shahriar Ghaffari | Optical system for treatment of vascular lesions |
| US5165418B1 (en) | 1992-03-02 | 1999-12-14 | Nikola I Tankovich | Blood sampling device and method using a laser |
| US5246437A (en) * | 1992-04-10 | 1993-09-21 | Abela George S | Cell treatment apparatus and method |
| US5643252A (en) * | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| US5279552A (en) * | 1993-01-11 | 1994-01-18 | Anton Magnet | Intradermal injection device |
| US5267985A (en) * | 1993-02-11 | 1993-12-07 | Trancell, Inc. | Drug delivery by multiple frequency phonophoresis |
| US5582184A (en) * | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
| US5445611A (en) | 1993-12-08 | 1995-08-29 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal delivery with ultrasound and chemical enhancers |
| US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
| ATE227146T1 (de) * | 1995-07-25 | 2002-11-15 | Massachusetts Inst Technology | Verbesserter transdermaler transport unter verwendung von ultraschall |
-
1996
- 1996-08-29 CN CNB961966718A patent/CN1174713C/zh not_active Expired - Lifetime
- 1996-08-29 AU AU68631/96A patent/AU707065B2/en not_active Expired
- 1996-08-29 BR BR9610012-5A patent/BR9610012A/pt not_active Application Discontinuation
- 1996-08-29 WO PCT/US1996/013865 patent/WO1997007734A1/en not_active Application Discontinuation
- 1996-08-29 IL IL12337996A patent/IL123379A/en not_active IP Right Cessation
- 1996-08-29 GB GB9702766A patent/GB2307414B/en not_active Expired - Lifetime
- 1996-08-29 TR TR1998/00347T patent/TR199800347T1/xx unknown
- 1996-08-29 CA CA002199002A patent/CA2199002C/en not_active Expired - Lifetime
- 1996-08-29 PT PT50110022T patent/PT1563788E/pt unknown
- 1996-08-29 JP JP51055297A patent/JP3899427B2/ja not_active Expired - Lifetime
- 1996-08-29 ES ES05011002.2T patent/ES2536459T3/es not_active Expired - Lifetime
- 1996-08-29 EP EP96929098A patent/EP0858285A4/en not_active Withdrawn
-
1998
- 1998-02-27 NO NO19980878A patent/NO334437B1/no not_active IP Right Cessation
- 1998-08-24 HK HK98110113A patent/HK1009321A1/xx not_active IP Right Cessation
-
2006
- 2006-02-15 JP JP2006038655A patent/JP2006192285A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PT1563788E (pt) | 2015-06-02 |
| GB9702766D0 (en) | 1997-04-02 |
| EP0858285A4 (en) | 2000-05-17 |
| NO980878D0 (no) | 1998-02-27 |
| GB2307414B (en) | 1998-03-11 |
| EP0858285A1 (en) | 1998-08-19 |
| CN1195276A (zh) | 1998-10-07 |
| JPH11511360A (ja) | 1999-10-05 |
| JP2006192285A (ja) | 2006-07-27 |
| HK1009321A1 (en) | 1999-05-28 |
| WO1997007734A1 (en) | 1997-03-06 |
| AU707065B2 (en) | 1999-07-01 |
| JP3899427B2 (ja) | 2007-03-28 |
| IL123379A (en) | 2002-04-21 |
| GB2307414A (en) | 1997-05-28 |
| NO980878L (no) | 1998-04-27 |
| AU6863196A (en) | 1997-03-19 |
| BR9610012A (pt) | 1999-12-21 |
| IL123379A0 (en) | 1998-09-24 |
| TR199800347T1 (xx) | 1998-05-21 |
| CA2199002A1 (en) | 1997-03-01 |
| CN1174713C (zh) | 2004-11-10 |
| ES2536459T3 (es) | 2015-05-25 |
| CA2199002C (en) | 1999-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6142939A (en) | Microporation of human skin for drug delivery and monitoring applications | |
| AU707065B2 (en) | Microporation of human skin for drug delivery and monitoring applications | |
| US6527716B1 (en) | Microporation of tissue for delivery of bioactive agents | |
| US7758561B2 (en) | Microporation of tissue for delivery of bioactive agents | |
| CA2789115C (en) | Microporation of tissue for delivery of bioactive agents | |
| US20020169394A1 (en) | Integrated tissue poration, fluid harvesting and analysis device, and method therefor | |
| US6419642B1 (en) | Irradiation enhanced permeation and delivery | |
| CA2329167C (en) | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue | |
| US20010050083A1 (en) | Irradiation enhanced permeation and delivery | |
| EP1563788B1 (en) | Microporation of human skin for drug delivery and monitoring applications | |
| RU2209031C2 (ru) | Формирование микропор в коже человека для доставки лекарственных препаратов и мониторинга | |
| WO2002026148A1 (en) | Irradiation enhanced permeation and collection | |
| WO2002026149A1 (en) | Irradiation enhanced permeation and delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: NITTO DENKO CORPORATION, JP |
|
| MK1K | Patent expired |